News

The U.S. Food & Drug Administration has granted orphan drug designation to Chicago-based Amphix Bio's treatment for acute ...
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary ...
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia . Clinical data showing unprecedented remission rates in newly diagnosed AML patient ...
SH-110, a liquid cancer treatment for glioma, earned orphan drug status from the FDA, helping patients who struggle to ...
"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Amphix Bio LLC has been granted U.S. FDA orphan drug designation for its lead candidate AMFX-200 for the treatment of acute spinal cord injury (SCI). AMFX-200 is an FGFR (fibroblast growth factor ...
The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral ...
The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing ...
KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and ...